Skip to content

Furiex Pharmaceuticals, Inc.

Delisted

CIK 1484478fmd_07E2KHYQ61C9EQZZ48WW4K5DJPManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2014, 17 periods

Latest annual · FY2013

Millions
Total revenues
71
Operating income
(24)
Net income
(30)
Free cash flow
(23)

Latest quarter · Q1 FY2014

Millions
Total revenues
6
Operating income
(11)
Net income
(13)
Free cash flow
(7)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2010 to FY2013
+99.2%

Furiex Pharmaceuticals, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2013FY2012ChangeSource
Revenue$71 million$40.5 million+75.3%10-K 2014-03-17 · proof
Operating income-$24.4 million-$40.3 million10-K 2014-03-17 · proof
Net income-$29.7 million-$42.9 million10-K 2014-03-17 · proof
Cash from operating activities-$23.1 million-$40.6 million10-K 2014-03-17 · proof
Free cash flow-$23.2 million-$40.7 million10-K 2014-03-17 · proof
Total assets$88.4 million$94.8 million-6.7%10-K 2014-03-17 · proof
Total liabilities$70 million$57.2 million+22.5%10-K 2014-03-17 · proof
Cash and cash equivalents$29.2 million$25.7 million+13.4%10-K 2014-03-17 · proof
Total debt$42 million$40 million+5%10-K 2014-03-17 · proof
What was Furiex Pharmaceuticals, Inc.'s revenue in fiscal 2013?
Furiex Pharmaceuticals, Inc. reported revenue of $71 million for fiscal 2013 (the year ended Dec 31, 2013), against $40.5 million the year before (+75.3%). Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What was Furiex Pharmaceuticals, Inc.'s operating income in fiscal 2013?
Furiex Pharmaceuticals, Inc. reported operating income of -$24.4 million for fiscal 2013 (the year ended Dec 31, 2013), against -$40.3 million the year before. Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What was Furiex Pharmaceuticals, Inc.'s net income in fiscal 2013?
Furiex Pharmaceuticals, Inc. reported net income of -$29.7 million for fiscal 2013 (the year ended Dec 31, 2013), against -$42.9 million the year before. Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What was Furiex Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2013?
Furiex Pharmaceuticals, Inc. reported cash from operating activities of -$23.1 million for fiscal 2013 (the year ended Dec 31, 2013), against -$40.6 million the year before. Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What was Furiex Pharmaceuticals, Inc.'s free cash flow in fiscal 2013?
Furiex Pharmaceuticals, Inc. reported free cash flow of -$23.2 million for fiscal 2013 (the year ended Dec 31, 2013), against -$40.7 million the year before. Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What are Furiex Pharmaceuticals, Inc.'s total assets?
As of Dec 31, 2013, Furiex Pharmaceuticals, Inc. reported total assets of $88.4 million, against $94.8 million a year earlier (-6.7%). Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What are Furiex Pharmaceuticals, Inc.'s total liabilities?
As of Dec 31, 2013, Furiex Pharmaceuticals, Inc. reported total liabilities of $70 million, against $57.2 million a year earlier (+22.5%). Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What are Furiex Pharmaceuticals, Inc.'s cash and cash equivalents?
As of Dec 31, 2013, Furiex Pharmaceuticals, Inc. reported cash and cash equivalents of $29.2 million, against $25.7 million a year earlier (+13.4%). Source: the 10-K filed with the SEC on Mar 17, 2014. SEC
What is Furiex Pharmaceuticals, Inc.'s total debt?
As of Dec 31, 2013, Furiex Pharmaceuticals, Inc. reported total debt of $42 million, against $40 million a year earlier (+5%). Source: the 10-K filed with the SEC on Mar 17, 2014. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1484478&period_type=annual&limit=5"

Information only, not investment advice.